Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

CytRx's INNO-206 Significantly Inhibits Pancreatic Cancer Growth In Animal Trials
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in the average primary tumor size in an animal model of pancreatic cancer, outperforming the broadly used chemotherapeutic drug doxorubicin, as well as the current standard of care in pancreatic cancer treatment, gemcitabine.

Cancer Vaccine Efficacy Enhanced Using Anti-Diabetic Drug Metformin
After a vaccination or an infection, the human immune system remembers to keep protecting against invaders it has already encountered, with the aid of specialized B-cells and T-cells. Immunological memory has long been the subject of intense study, but the underlying cellular mechanisms regulating the generation and persistence of long-lived memory T cells remain largely undefined. Now, University of Pennsylvania School of Medicine researchers have found that a common anti-diabetic drug might enhance the effectiveness of vaccines. The findings are described this week in an advanced online publication of Nature.
News of the day
FDA Accepts For Review Spectrum's Response On ZEVALIN As A Class 1 Submission, And Establishes September 7, 2009 As Decision Date
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a focus on oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the resubmission to the Company"s supplement to the biologics license application for ZEVALIN (ibritumomab tiuxetan) in the first line consolidation setting on July 8, 2009. The FDA considers the review as a Class 1 submission to their complete response letter of July 2, 2009. Therefore, the user fee goal date is September 7, 2009.
Oncology

Increased Vascular Endothelial Growth Factor Expression In Patients With Bladder Pain Syndrome/Interstitial Cystitis

UroToday.com - Angiogenesis is thought to be important in many chronic inflammatory disorders, including diabetic retinopathy, atherosclerosis, and inflammatory bowel disease. It has also been suggested that the angiogenic components of these diseases contribute to and exacerbate disease conditions. Increased levels of vascular endothelial growth factor (VEGF) have been detected in patients with asthma and have been shown to be correlated with the severity of the disease. Anti-VEGF therapy has been shown to ameliorate inflammation in animal models of chronic inflammatory bowel disease. This background forms the prelude to a very interested study by Kiuchi and colleagues from Osaka, Japan. The authors note that VEGF is a crucial angiogenic factor, and its secretion is strictly regulated to form functional vessel networks. Pericytes are perivascular cells that wrap around microvessels and contact endothelial cells through discontinuities in the shared basement membrane. When vessels lose pericytes, they become tortuous and hemorrhagic. Abnormal activity of VEGF contributes to insufficient coverage of pericytes, resulting in leaky and hemorrhagic vessels. Kiuchi and coworkers examined biopsy specimens from 30 patients with BPS/IC who demonstrated glomerulations on hydrodistention, and compared them with biopsies from 10 control patients who had isolated bladder tumors and no symptoms of voiding dysfunction. None of the control patients had glomerulations after distention. Immunohistochemical analysis for VEGF expression, microvessel density and immature microvessels was performed. Pericyte coverage of microvessels in the specimens was used as an indicator of mature microvessels, and pericytes were identified by double-immunohistochemistry for CD34 and í±-smooth muscle actin. The researchers generated data that allowed them to conclude that there is an increased VEGF and immature vascularization in the bladder biopsies from patients with BPS/IC, and VEGF expression was associated with the degree of pain experienced by the patients. Taken together, Kiuchi believes that VEGF might contribute to pain and promote the formation of immature vessels in the bladder of patients with BPS/IC. This increased immature vascularization might have a potential role in glomerulations in these patients. Kiuchi H, Tsujimura A, Takao T, Yamamoto K, Nakayama J, Miyagawa Y, Nonomura N, Takeyama M, Okuyama A BJU Int. 2009 Mar 4. (Epub ahead of print) doi:10.1111/j.1464-410X.2009.08467.x Written by UroToday.com Contributing Editor Philip M. Hanno, MD, MPH UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009